In a child with a history of transient neonatal hyperinsulinemia and negative genetic testing, who now presents with seizures, a hemoglobin A1c of 5.1% and a blood glucose of 94 mg/dL (initially 123 mg/dL and rising to 166 mg/dL after seizures), what is the appropriate acute management?

Acute Management: Seizure Control and Metabolic Evaluation

In this child with transient neonatal hyperinsulinemia (now resolved) presenting with seizures and normal glucose/A1C, treat the seizures as acute provoked seizures unrelated to hypoglycemia using standard neonatal seizure protocols, starting with phenobarbital as first-line therapy. 1

Clinical Reasoning

The clinical picture here is critical to parse correctly:

• Current glucose status is normal: Blood glucose of 94 mg/dL with A1C 5.1% definitively rules out hypoglycemia as the seizure etiology
• Post-ictal hyperglycemia is expected: The rise to 123-166 mg/dL after seizures represents physiologic stress response, not diabetes
• Transient neonatal hyperinsulinemia has resolved: Negative genetic workup during NICU stay and current normal glucose homeostasis confirm this was a self-limited condition

The transient hyperinsulinemia is a red herring in this presentation. These conditions typically resolve within weeks to months and are associated with perinatal stress factors 2, 3. With negative genetic testing, permanent forms like KATP-HI, HI/HA syndrome, or other genetic hyperinsulinism are excluded 3, 4, 5.

Immediate Seizure Management

First-line treatment:

• Phenobarbital 20 mg/kg IV as initial loading dose 1
• Can repeat with additional 20 mg/kg if seizures persist 1
• Phenobarbital demonstrates 80% efficacy for seizure control in neonates with moderate-quality evidence 1

If seizures persist after phenobarbital:

• Second-line options: Phenytoin or levetiracetam 1
• Levetiracetam may be preferred if cardiac concerns exist 1
• Consider sodium channel blocker (phenytoin/carbamazepine) only if channelopathy suspected based on EEG features 1

Critical caveat: EEG confirmation is essential for accurate diagnosis and treatment monitoring 1. Only focal clonic and focal tonic seizures can be diagnosed clinically; all other seizure types require EEG or amplitude-integrated EEG (aEEG) confirmation 1.

Metabolic Workup Priority

While treating seizures, simultaneously evaluate for alternative etiologies:

Essential investigations:

• EEG to confirm seizure type and guide therapy
• Neuroimaging (MRI brain) to identify structural causes
• Metabolic screen if no clear etiology emerges
• Consider pyridoxine trial (add-on to antiseizure medication) if seizures are refractory to second-line therapy without identified cause 1

Pyridoxine consideration: In neonates with seizures unresponsive to second-line ASM without identified etiology, attempt pyridoxine trial as add-on therapy 1. If vitamin B6-dependent epilepsy suspected and pyridoxine fails, consider pyridoxal 5'-phosphate (PLP) trial 1.

Duration of Antiseizure Medication

Following cessation of acute provoked seizures without evidence of neonatal-onset epilepsy, discontinue antiseizure medications before discharge home, regardless of MRI or EEG findings 1. This represents updated guidance with high level of expert agreement 1.

The goal is shortest possible phenobarbital exposure due to potential adverse effects, ensuring medication is only used when necessary 1.

Common Pitfalls to Avoid

1. Do not attribute current seizures to resolved hyperinsulinemia: The normal glucose and A1C exclude hypoglycemia
2. Do not delay seizure treatment: Waiting for extensive metabolic workup risks increased seizure burden and worse neurodevelopmental outcomes
3. Do not continue antiseizure medications unnecessarily: If acute provoked seizures resolve without evidence of epilepsy, discontinue before discharge 1
4. Do not rely on clinical diagnosis alone: EEG confirmation is mandatory for accurate seizure identification and treatment assessment 1